Clinical Trial Goal
To find out:
- The highest dose of ARV-393 that's safe to give
- If ARV-393 is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have B-cell NHL that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Waldenström macroglobulinemia
- Have not had an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
ARV-393 is a B-cell lymphoma 6 (BCL6) protein degrader.
Glofitamab is a bispecific monoclonal antibody that targets CD 3 and CD20 on certain cells.
You'll be placed in 1 of 2 groups:
Glofitamab is a bispecific monoclonal antibody that targets CD 3 and CD20 on certain cells.
You'll be placed in 1 of 2 groups:
- Group 1 - ARV-393
- Group 2 - ARV-393 plus glofitamab
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- ARV-393 – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Glofitamab - Group 2 only - Given as an intravenous (IV) infusion
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved ARV-393.
Locations
Sponsors
lead: Arvinas Inc.
